Alumis' lupus drug fails mid-stage trial goal

ALMS•2026-09-01

Mid-stage lupus trial miss

Alumis said on Tuesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with a chronic autoimmune disease called systemic lupus erythematosus.

Alumis' lupus drug fails mid-stage trial goal

Mid-stage lupus trial miss

Related News

Aduro operating loss widens to CAD $12.43 million in Q4 FY26; revenue turns to no revenue

Yext Inc Q2 Adjusted EPS USD 0.21

Vera Bradley sets fiscal Q2 earnings release, conference call

Relmada Therapeutics to hold one-on-one investor meetings at Wells Fargo Healthcare Conference

VivoSim Labs plans rat liver model expansion for NAMkind platform